Status:
COMPLETED
Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
Brief Summary
This trial is conducted in Asia. The aim of this study is to investigate the safety profile of liraglutide (Victoza®) under normal conditions of use in Korean subjects with type 2 diabetes mellitus.
Eligibility Criteria
Inclusion
- Subjects with T2DM (Type 2 Diabetes Mellitus), including newly-diagnosed subjects, who require treatment with Victoza® according to the clinical judgment of their treating physician
- Subjects (and/or parents or the subject's legally acceptable representative) who are capable of giving study-specific signed informed consent before any collection of information
Exclusion
- Subjects with a hypersensitivity to Victoza® or to any of the excipients
- Subjects who are pregnant, breast feeding or have the intention of becoming pregnant within the study periods
- Subjects with personal or family history of medullary thyroid carcinoma (MTC)
- Subjects with multiple endocrine neoplasia syndrome type 2 (MEN2)
Key Trial Info
Start Date :
November 20 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 8 2017
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT01821846
Start Date
November 20 2013
End Date
March 8 2017
Last Update
August 21 2017
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Pyungchon-Dong 896, Dongan-Gu, South Korea, 431-796
2
Novo Nordisk Investigational Site
Seoul, South Korea, 02447
3
Novo Nordisk Investigational Site
Seoul, South Korea, 03080
4
Novo Nordisk Investigational Site
Seoul, South Korea, 150-950